News stories about AC Immune (NASDAQ:ACIU) have been trending somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. AC Immune earned a news impact score of 0.20 on Accern’s scale. Accern also gave news headlines about the company an impact score of 47.5079092692308 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
ACIU has been the topic of a number of analyst reports. HC Wainwright initiated coverage on shares of AC Immune in a research note on Thursday, April 5th. They set a “buy” rating and a $18.00 price objective on the stock. BidaskClub downgraded shares of AC Immune from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 19th. Zacks Investment Research upgraded shares of AC Immune from a “sell” rating to a “hold” rating in a research note on Monday, February 5th. Finally, Credit Suisse Group downgraded shares of AC Immune from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $18.00 to $14.00 in a research note on Friday, March 23rd.
Shares of ACIU traded down $0.10 during mid-day trading on Friday, reaching $10.42. The company had a trading volume of 47,817 shares, compared to its average volume of 50,104. AC Immune has a 1-year low of $6.03 and a 1-year high of $13.91. The company has a market cap of $597.64, a P/E ratio of -34.73 and a beta of 2.21.
WARNING: This piece of content was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3379755/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-ac-immune-aciu-stock-price.html.
AC Immune Company Profile
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms generates antibodies and small molecules that selectively bind to misfolded proteins to address neurodegenerative indications, such as Alzheimer's (AD), Parkinson's, down syndrome, and glaucoma diseases.
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.